Dovitinib (TKI258), a multi-target angiokinase inhibitor, is effective regardless of KRAS or BRAF mutation status in colorectal cancer

Introduction: We aimed to determine whether KRAS and BRAF mutant colorectal cancer (CRC) cells exhibit distinct sensitivities to the multi-target angiokinase inhibitor, TKI258 (dovitinib). Materials and methods: We screened 10 CRC cell lines by using receptor tyrosine kinase (RTK) array to identify...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Am J Cancer Res
Hoofdauteurs: Lee, Choong-Kun, Lee, Myung Eun, Lee, Won Suk, Kim, Jeong Min, Park, Kyu Hyun, Kim, Tae Soo, Lee, Kang Young, Ahn, Joong Bae, Chung, Hyun Cheol, Rha, Sun Young
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: e-Century Publishing Corporation 2014
Onderwerpen:
Original Article
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4300687/
https://ncbi.nlm.nih.gov/pubmed/25628921
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items